東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Oral and transdermal delivery of low...

Lanke, Satya Surya Shankar.

FindBook

Google Book

Amazon

博客來

Oral and transdermal delivery of low molecular weight heparin.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Oral and transdermal delivery of low molecular weight heparin./
作者:	Lanke, Satya Surya Shankar.
面頁冊數:	140 p.
附註:	Source: Dissertation Abstracts International, Volume: 71-04, Section: B, page: 2344.
Contained By:	Dissertation Abstracts International71-04B.
標題:	Health Sciences, Pharmacy. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3405950
ISBN:	9781109724769

Oral and transdermal delivery of low molecular weight heparin.
Lanke, Satya Surya Shankar.

Oral and transdermal delivery of low molecular weight heparin. - 140 p.

Source: Dissertation Abstracts International, Volume: 71-04, Section: B, page: 2344.

Thesis (Ph.D.)--Mercer University, 2010.

The clinical use of low molecular weight heparin (LMWH) is currently limited owing to their parenteral administration. However there is an opportunity to deliver this anticoagulant drug in a patient compliant route. In our effort to deliver LMWH in a patient compliant route we had investigated the delivery of this drug via oral and transdermal routes.

ISBN: 9781109724769Subjects--Topical Terms:

1017737
Health Sciences, Pharmacy.

Oral and transdermal delivery of low molecular weight heparin.
LDR:03744nam 2200289 4500 001 1397264
005 20110719084840.5
008 130515s2010 ||||||||||||||||| ||eng d
020 $a 9781109724769
035 $a (UMI)AAI3405950
035 $a AAI3405950
040 $a UMI $c UMI
100 1 $a Lanke, Satya Surya Shankar. $3 1676081
245 1 0 $a Oral and transdermal delivery of low molecular weight heparin.
300 $a 140 p.
500 $a Source: Dissertation Abstracts International, Volume: 71-04, Section: B, page: 2344.
500 $a Adviser: James Grady Strom.
502 $a Thesis (Ph.D.)--Mercer University, 2010.
520 $a The clinical use of low molecular weight heparin (LMWH) is currently limited owing to their parenteral administration. However there is an opportunity to deliver this anticoagulant drug in a patient compliant route. In our effort to deliver LMWH in a patient compliant route we had investigated the delivery of this drug via oral and transdermal routes.
520 $a The primary reason for minimal transdermal delivery of LMWH is because of its macromolecular structure. The skin barrier should be maneuvered to transport larger molecules across stratum corneum. Various strategies were employed to deliver LMWH transdermally. Physical approaches such as iontophoresis, ultrasound and microneedles as well as combination strategies were employed to deliver LMWH. The combinatorial effect of iontophoresis on soluble maltose microneedle pretreated skin had shown a significant enhancement. Metallic microneedles were also used to demonstrate the effect of barrier perturbation on transdermal delivery of LMWH. The feasibility of LMWH microemulsions on transdermal delivery was also investigated. Aerosol OT was employed as a surfactant and isopropyl myristate as an oil in microemulsion preparation. In vitro and in vivo studies demonstrated the microemulsions improved the transcutaneous penetration there by enhanced the LMWH delivery.
520 $a Apart from the transdermal delivery, oral delivery is also one of the most patient compliant routes. Nevertheless the poor oral bioavailability of LMWH is major hurdle for its delivery. This is attributed to the degradation in the acidic pH of the gastrointestinal tract and low permeability across the gastrointestinal epithelial membrane due to relatively large molecular weight and high charge density are the primary reasons. A novel oral formulation of LMWHs can improve the oral bioavailability of LMWH. The hypothesis of this work is that the oral delivery of LMWH can be improved by encapsulation of LMWH into microspheres and by the use of absorption enhancers. This hypothesis was tested by employing papain as absorption enhancer. The permeability studies using Caco-2 monolayer suggested that LMWH has low permeability through the membrane. The permeability was enhanced in the presence of the absorption enhancer. In vitro regional permeability studies across the rat gastrointestinal tract tissue segments revealed that papain acts as an absorption enhancer in permeation of LMWH. Microsphere formulations were spray dried using biodegradable bovine serum albumin as a matrix. Microspheres were characterized for particle size, charge, morphology, yield, encapsulation efficiency and drug release. In vivo absorption studies in rats revealed that the microsphere formulation increased the oral bioavailability of LMWH as compared to control. MS.3 formulation reached therapeutic plasma anti-factor Xa levels (>0.14 IU/mL).
590 $a School code: 1160.
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0572
710 2 $a Mercer University. $3 1265016
773 0 $t Dissertation Abstracts International $g 71-04B.
790 1 0 $a Strom, James Grady, $e advisor
790 $a 1160
791 $a Ph.D.
792 $a 2010
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3405950